USPTO serial 88981217
SLURM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- LOOK, JEFFREY J
- Law office
- TMO LAW OFFICE 126- SENIOR ATTORNEY
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with SLURM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Thomas F. Zuber
Thomas F. Zuber Zuber Lawler LLP350 South Grand Avenue, 32nd FloorLos Angeles, CA 90071UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicinal herbs, all of the foregoing containing cannabis or cannabis derivatives with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing containing, as an inactive ingredient, CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not including any products not conforming to an OTC Monograph, and all of the foregoing not including any goods noncompliant with U.S. federal law; Orally-consumed medicinal herbs in the nature of dietary supplements, all of the foregoing containing cannabis or cannabis derivatives with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing containing only naturally-occurring trace levels of CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not including any goods noncompliant with U.S. federal law; Medicinal herbs, all of the foregoing containing, as an inactive ingredient, cannabichromene derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not containing CBD, and all of the foregoing not including any products not conforming to an OTC Monograph, and all of the foregoing not including any goods noncompliant with U.S. federal law; Orally-consumed medicinal herbs in the nature of dietary supplements, all of the foregoing containing cannabichromene derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not containing CBD, and all of the foregoing not including any goods noncompliant with U.S. federal law; Orally-consumed medicinal herbs in the nature of dietary supplements, all of the foregoing containing cannabichromene derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing containing only naturally-occurring trace levels of CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not including any goods noncompliant with U.S. federal law; Medicinal herbs, all of the foregoing containing, as an inactive ingredient, cannabitriol derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not containing CBD, and all of the foregoing not including any products not conforming to an OTC Monograph, and all of the foregoing not including any goods noncompliant with U.S. federal law; Orally-consumed medicinal herbs in the nature of dietary supplements, all of the foregoing containing cannabitriol derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not containing CBD, and all of the foregoing not including any goods noncompliant with U.S. federal law; Orally-consumed medicinal herbs in the nature of dietary supplements, all of the foregoing containing cannabitriol derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing containing only naturally-occurring trace levels of CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not including any goods noncompliant with U.S. federal law; Medicinal herbs, all of the foregoing containing, as an inactive ingredient, cannabicyclol derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not containing CBD, and all of the foregoing not including any products not conforming to an OTC Monograph, and all of the foregoing not including any goods noncompliant with U.S. federal law; Orally-consumed medicinal herbs in the nature of dietary supplements, all of the foregoing containing cannabicyclol derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not containing CBD, and all of the foregoing not including any goods noncompliant with U.S. federal law; Orally-consumed medicinal herbs in the nature of dietary supplements, all of the foregoing containing cannabicyclol derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing containing only naturally-occurring trace levels of CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not including any goods noncompliant with U.S. federal law; Medicinal herbs, all of the foregoing containing, as an inactive ingredient, CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing not including any products not conforming to an OTC Monograph, and all of the foregoing not including any goods noncompliant with U.S. federal law; Orally-consumed medicinal herbs in the nature of dietary supplements, all of the foregoing containing CBD derived from cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis, and all of the foregoing containing only naturally-occurring trace levels of CBD, and all of the foregoing not including any goods noncompliant with U.S. federal law | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 26, 2024 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 26, 2024 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 28, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 28, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 28, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 7, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 7, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 7, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 7, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 7, 2021 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Mar 31, 2021 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Mar 31, 2021 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Mar 31, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 30, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 30, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 8, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 8, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 8, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 1, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 1, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 1, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 22, 2020 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Jul 21, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 16, 2020 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Jul 16, 2020 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jul 16, 2020 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 16, 2020 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| May 8, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 7, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 7, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 7, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 5, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| May 24, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| May 15, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 24, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 9, 2019 | NWAP | NEW APPLICATION ENTERED | — |